Show simple item record

dc.contributor.author Vaine, M
dc.contributor.author Wang, S
dc.contributor.author Liu, Q
dc.contributor.author Arthos, J
dc.contributor.author Montefiori, D
dc.contributor.author Goepfert, P
dc.contributor.author McElrath, MJ
dc.contributor.author Lu, S
dc.coverage.spatial United States
dc.date.accessioned 2011-06-21T17:32:20Z
dc.date.issued 2010-11-09
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/21085486
dc.identifier.citation PLoS One, 2010, 5 (11), pp. e13916 - ?
dc.identifier.uri http://hdl.handle.net/10161/4583
dc.description.abstract In the current report, we compared the specificities of antibody responses in sera from volunteers enrolled in three US NIH-supported HIV vaccine trials using different immunization regimens. HIV-1 Env-specific binding antibody, neutralizing antibody, antibody-dependent cell-mediated cytotoxicity (ADCC), and profiles of antibody specificity were analyzed for human immune sera collected from vaccinees enrolled in the NIH HIV Vaccine Trial Network (HVTN) Study #041 (recombinant protein alone), HVTN Study #203 (poxviral vector prime-protein boost), and the DP6-001 study (DNA prime-protein boost). Vaccinees from HVTN Study #041 had the highest neutralizing antibody activities against the sensitive virus along with the highest binding antibody responses, particularly those directed toward the V3 loop. DP6-001 sera showed a higher frequency of positive neutralizing antibody activities against more resistant viral isolate with a significantly higher CD4 binding site (CD4bs) antibody response compared to both HVTN studies #041 and #203. No differences were found in CD4-induced (CD4i) antibody responses, ADCC activity, or complement activation by Env-specific antibody among these sera. Given recent renewed interest in realizing the importance of antibody responses for next generation HIV vaccine development, different antibody profiles shown in the current report, based on the analysis of a wide range of antibody parameters, provide critical biomarker information for the selection of HIV vaccines for more advanced human studies and, in particular, those that can elicit antibodies targeting conformational-sensitive and functionally conserved epitopes.
dc.format.extent e13916 - ?
dc.language eng
dc.language.iso en_US en_US
dc.relation.ispartof PLoS One
dc.relation.isversionof 10.1371/journal.pone.0013916
dc.subject AIDS Vaccines
dc.subject Antibodies, Neutralizing
dc.subject Antibody Specificity
dc.subject Antibody-Dependent Cell Cytotoxicity
dc.subject Enzyme-Linked Immunosorbent Assay
dc.subject HIV Antibodies
dc.subject HIV Envelope Protein gp120
dc.subject HIV Infections
dc.subject HIV-1
dc.subject Humans
dc.title Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.
dc.title.alternative en_US
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-11-9 en_US
duke.description.endpage e13916 en_US
duke.description.issue 11 en_US
duke.description.startpage e13916 en_US
duke.description.volume 5 en_US
dc.relation.journal Plos One en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/21085486
pubs.issue 11
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery/Surgery, Surgical Sciences Section for AIDS Research & Development
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Human Vaccine Institute
pubs.publication-status Published online
pubs.volume 5
dc.identifier.eissn 1932-6203

Files in this item

This item appears in the following Collection(s)

Show simple item record